Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  2005-08-16

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1073/PNAS.0505497102PMID 16087865PMCID PMC1188011
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mapping non-class II H2-linked loci for type 1 diabetes in nonobese diabetic mice.

  2004cited by this paper
• Local expression of B7-H1 promotes organ-specific autoimmunity and transplant rejection.

  2004cited by this paper
• Aromatase-deficient mice spontaneously develop a lymphoproliferative autoimmune disease resembling Sjogren's syndrome.

  2004cited by this paper
• PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells.

  2004cited by this paper
• Peritoneal B cells govern the outcome of diabetes in non‐obese diabetic mice

  2004cited by this paper
• Dissecting autoimmune diabetes through genetic manipulation of non-obese diabetic mice

  2003cited by this paper
• Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice

  2003cited by this paper
• Dynamics of Pathogenic and Suppressor T Cells in Autoimmune Diabetes Development

  2003cited by this paper
• The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice

  2003cited by this paper
• PD-1 Inhibits Antiviral Immunity at the Effector Phase in the Liver

  2003cited by this paper
• Regulation of PD‐1, PD‐L1, and PD‐L2 expression during normal and autoimmune responses

  2003cited by this paper
• Susceptibility genes in the pathogenesis of murine lupus

  2002cited by this paper
• Pathogenesis of Sjögren's syndrome: characteristics of different mouse models for autoimmune exocrinopathy.

  2002cited by this paper
• Notch–RBP-J signaling is involved in cell fate determination of marginal zone B cells

  2002cited by this paper
• Genetics of autoimmune diseases in humans and in animal models.

  2002cited by this paper
• Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

  2002cited by this paper
• New regulatory co-receptors: inducible co-stimulator and PD-1.

  2002cited by this paper
• The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses.

  2002cited by this paper
• Understanding autoimmune diabetes: insights from mouse models.

  2002cited by this paper
• Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.

  2001cited by this paper
• PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine

  2001cited by this paper
• Disease resistant, NOD-related strains reveal checkpoints of immunoregulation in the pancreas

  2001cited by this paper
• Facilitation of β Selection and Modification of Positive Selection in the Thymus of Pd-1–Deficient Mice

  2000cited by this paper
• B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes.

  2000cited by this paper
• Mapping autoimmunity genes.

  1999cited by this paper
• Genetic dissection of systemic lupus erythematosus.

  1999cited by this paper
• Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.

  1999cited by this paper
• Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses.

  1998cited by this paper
• A search for type 1 diabetes susceptibility genes in families from the United Kingdom

  1998cited by this paper
• Local expression of TNFalpha in neonatal NOD mice promotes diabetes by enhancing presentation of islet antigens.

  1998cited by this paper
• New genetic loci that control susceptibility and symptoms of experimental allergic encephalomyelitis in inbred mice.

  1998cited by this paper
• The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD.

  1997cited by this paper
• Acceleration of spontaneous diabetes in TCR-beta-transgenic nonobese diabetic mice by beta-cell cytotoxic CD8+ T cells expressing identical endogenous TCR-alpha chains.

  1996cited by this paper
• Crosses of NOD Mice With the Related NON Strain: A Polygenic Model for IDDM

  1995cited by this paper
• Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results

  1995cited by this paper
• Crosses of NOD mice with the related NON strain. A polygenic model for IDDM.

  1995cited by this paper
• Use of recombinant congenic and congenic strains of NOD mice to identify a new insulin-dependent diabetes resistance gene

  1994cited by this paper
• Genetic analysis of autoimmune type 1 diabetes mellitus in mice

  1991cited by this paper

• The role of programmed cell death 1 in autoimmune diseases: mechanisms and therapeutic implications

  2026cites this paper
• Calorie Restriction Upregulates Islet PD-L1 Signaling and Decreases the Risk of Auto-immune Diabetes Onset in NOD Mice

  2026cites this paper
• Preclinical mouse models of immune checkpoint inhibitor-associated myocarditis

  2025cites this paper
• Immune checkpoint changes correlate with the progression and prognosis of amyotrophic lateral sclerosis

  2025cites this paper
• Genome-Wide Aggregated Trans Effects Analysis for Circulating Proteins Indicates a Key Role of Immune Checkpoints in Type 1 Diabetes

  2025cites this paper
• Identification of anti-mouse PD-1 agonist antibodies that inhibit T cell activation

  2025cites this paper
• Circulating T Cell Subsets in Type 1 Diabetes

  2025cites this paper
• A vascular-associated fibroblastic cell controls pancreatic islet immunity.

  2025cites this paper
• An interleukin-27-centered cytokine circuit regulates macrophage and T cell interactions in autoimmune diabetes

  2025cites this paper
• CD8 T cells mediate immunosurveillance for neoantigen+ epithelial stem cells in the colon

  2025cites this paper
• Programmed Death-Ligand 1 in Renal Allografts With Antibody-Mediated Rejection.

  2025cites this paper
• Immune Checkpoint Inhibitor-Induced Diabetes Mellitus—A Brief Review and Three Case Reports

  2025cites this paper
• The PD-1/PD-L1 pathway and Epstein–Barr virus

  2025cites this paper
• T Cell Exhaustion.

  2024cites this paper
• Applications of CRISPR Epigenome Editors in Tumor Immunology and Autoimmunity.

  2024cites this paper
• Toxicity in the era of immune checkpoint inhibitor therapy

  2024cites this paper
• Programmed cell death-1-modified pig developed using electroporation-mediated gene editing for in vitro fertilized zygotes

  2024cites this paper
• Human inherited PD-L1 deficiency is clinically and immunologically less severe than PD-1 deficiency

  2024cites this paper
• Checkpoint Inhibitor-Induced Autoimmune Diabetes: An Autoinflammatory Disease.

  2024cites this paper
• PD-L1 and PD-1 in Immune Regulation and Their Implications in Blood Cancers

  2024cites this paper
• Immune checkpoint inhibitors in infectious disease

  2024cites this paper
• Regulatory role of PI16 in autoimmune arthritis and intestinal inflammation: implications for Treg cell differentiation and function

  2024cites this paper
• TIGIT acts as an immune checkpoint upon inhibition of PD1 signaling in autoimmune diabetes

  2024cites this paper
• Immune checkpoint inhibitors-associated diabetes and ketoacidosis were found in FAERS: A Real-World Evidence Database Study.

  2024cites this paper
• Predictive Biomarkers and Resistance Mechanisms of Checkpoint Inhibitors in Malignant Solid Tumors

  2024cites this paper
• Murine MHC-Deficient Nonobese Diabetic Mice Carrying Human HLA-DQ8 Develop Severe Myocarditis and Myositis in Response to Anti-PD-1 Immune Checkpoint Inhibitor Cancer Therapy.

  2024cites this paper
• Pathophysiology, diagnosis, and management of immune checkpoint inhibitor-induced diabetes mellitus

  2024cites this paper
• Immune Checkpoint Inhibitors PD-1/PDL-1 and CTLA-4 as a Novel Solution in Breast Cancer Treatment: A Review Study

  2024cites this paper
• Nature's Arsenal: Harnessing the Capacity of Phytochemicals to Enhance Immune Checkpoint Inhibitor Therapy of Cancers: An Especial Attention to Brain Malignancies.

  2024cites this paper
• Immune checkpoint inhibitor‑associated diabetes mellitus in patients with HCC: Report of three cases and literature review

  2024cites this paper
• The harmful effect of ankylosing spondylitis on diabetes mellitus: new evidence from the Mendelian randomization analysis

  2024cites this paper
• The B7:CD28 family and friends: Unraveling coinhibitory interactions.

  2024cites this paper
• Early allogeneic immune modulation after establishment of donor hematopoietic cell-induced mixed chimerism in a nonhuman primate kidney transplant model

  2024cites this paper
• Immune checkpoint receptors in autoimmunity.

  2023cites this paper
• Immune checkpoint inhibitor-induced diabetes mellitus with nivolumab

  2023cites this paper
• Mechanisms and therapeutic strategies of immune checkpoint molecules and regulators in type 1 diabetes

  2023cites this paper
• The Role of BCL-2 and PD-1/PD-L1 Pathway in Pathogenesis of Myelodysplastic Syndromes

  2023cites this paper
• Novel PD-L1/BTLA Checkpoint Axis Exploited for Bacterial Immune Escape by Restraining CD8+ T Cell-Initiated Adaptive Immunity in Zebrafish.

  2023cites this paper
• The implication of targeting PD-1:PD-L1 pathway in treating sepsis through immunostimulatory and anti-inflammatory pathways

  2023cites this paper
• Programmed death receptor 1 (PD‐1) ligand Fc fusion proteins reduce T‐cell proliferation in vitro independently of PD‐1

  2023cites this paper
• Generation and Immuno-inflammatory Checkpoints in Oral Cavity Cancers

  2023cites this paper
• Selective ablation of thymic and peripheral Foxp3+ regulatory T cell development

  2023influential citation
• A review on mesenchymal stem cell-based therapies for autoimmune disorders

  2023cites this paper
• Successful treatment of nivolumab and ipilimumab triggered type 1 diabetes by using sodium-glucose transporter 2 inhibitor: a case report and systematic review

  2023cites this paper
• Structure of PD1 and its mechanism in the treatment of autoimmune diseases

  2023cites this paper
• A small molecule inhibitor of PTP1B and PTPN2 enhances T cell anti-tumor immunity

  2023cites this paper
• Gastrointestinal mucosal toxicities from immune checkpoint inhibitors: Current understanding and future directions

  2023cites this paper
• Immune-related adverse effects of checkpoint immunotherapy and implications for the treatment of patients with cancer and autoimmune diseases

  2023cites this paper
• Single-cell profiling reveals unique features of diabetogenic T cells in anti-PD-1-induced type 1 diabetes mice

  2023cites this paper
• Different Prognostic Role of Soluble PD-L1 in the Course of Severe and Non-Severe COVID-19

  2023cites this paper
• Outline of Salivary Gland Pathogenesis of Sjögren’s Syndrome and Current Therapeutic Approaches

  2023cites this paper
• A small molecule inhibitor of PTP1B and PTPN2 enhances T cell anti-tumor immunity

  2023cites this paper
• Presence of PD-1 similarity genes in monocytes may promote the development of type 1 diabetes mellitus and poor prognosis of pancreatic cancer

  2023cites this paper
• Successful treatment with carboplatin and paclitaxel in melanoma progression after immune-related adverse events.

  2023cites this paper
• Autoimmunity: A New Focus on Nasal Polyps

  2023cites this paper
• Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies

  2023cites this paper
• Identification of the functional PD-L1 interface region responsible for PD-1 binding and initiation of PD-1 signaling

  2023cites this paper
• Single cell transcriptomic analysis of Graves' disease thyroid glands reveals the broad immunoregulatory potential of thyroid follicular and stromal cells and implies a major re-interpretation of the role of aberrant HLA class II expression in autoimmunity.

  2023cites this paper
• Programmed Cell Death Protein 1/Programmed Cell Death Protein Ligand 1 Immunosuppressants in Advanced Non-Small Cell Lung Cancer Research Progress in Treatment

  2022cites this paper
• The protective effect of total glucosides of white paeony capsules on experimental autoimmune encephalomyelitis.

  2022cites this paper
• Diabetes induced by checkpoint inhibition in nonobese diabetic mice can be prevented or reversed by a JAK1/JAK2 inhibitor

  2022cites this paper
• Development of Fulminant Type 1 Diabetes Mellitus in the Course of Treatment with Atezolizumab for Hepatocellular Carcinoma

  2022cites this paper
• Re-Enlightenment of Fulminant Type 1 Diabetes under the COVID-19 Pandemic

  2022cites this paper
• Current studies and future promises of PD-1 signal inhibitors in cervical cancer therapy.

  2022cites this paper
• Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials

  2022cites this paper
• In or out of control: Modulating regulatory T cell homeostasis and function with immune checkpoint pathways

  2022cites this paper
• The PD-1/PD-L1 Pathway: A Perspective on Comparative Immuno-Oncology

  2022cites this paper
• Insights Into the Host Contribution of Endocrine Associated Immune-Related Adverse Events to Immune Checkpoint Inhibition Therapy

  2022cites this paper
• Islet allografts expressing a PD‐L1 and IDO fusion protein evade immune rejection and reverse preexisting diabetes in immunocompetent mice without systemic immunosuppression

  2022cites this paper
• The genetic influence of PD-1/PD-L1 axis single nucleotide polymorphisms on the incidence of type 1 diabetes mellitus in pediatric Egyptian patients

  2022cites this paper
• Immune cells and their inflammatory mediators modify β cells and cause checkpoint inhibitor–induced diabetes

  2022cites this paper
• PD-1/PD-L Axis in Neuroinflammation: New Insights

  2022cites this paper
• IMMUNE CHECKPOINT INHIBITORS RELATED ENDOCRINE ADVERSE EVENTS

  2022cites this paper
• Targeting Protein Tyrosine Phosphatase 22 Does Not Enhance the Efficacy of Chimeric Antigen Receptor T Cells in Solid Tumors

  2022cites this paper
• Cardiac myosin-specific autoimmune T cells contribute to immune-checkpoint-inhibitor-associated myocarditis

  2022cites this paper
• Checkpoint Inhibitors and Induction of Celiac Disease-like Condition

  2022cites this paper
• Type 1 diabetes related to immune checkpoint inhibitors.

  2022cites this paper
• PD-1 inhibitor-associated type 1 diabetes: A case report and systematic review

  2022cites this paper
• Sintilimab-induced autoimmune diabetes: A case report and review of the literature

  2022cites this paper
• 免疫检查点抑制剂相关糖尿病2例报道及文献回顾

  2022cites this paper
• Inborn Errors of Immunity and Their Phenocopies: CTLA4 and PD-1

  2022cites this paper
• A Review on the Application of PD-1 Blockade in EBV-Associated Nasopharyngeal Carcinoma Immunotherapy

  2022cites this paper
• Vitamin D can reduce severity in COVID-19 through regulation of PD-L1

  2022cites this paper
• Activation pathways that drive CD4+ T cells to break tolerance in autoimmune diseases *

  2022cites this paper
• Immune checkpoint inhibitor–induced diabetes mellitus with pembrolizumab

  2022cites this paper
• Immunogenetics of Lupus Erythematosus.

  2022cites this paper
• PD-1 agonism by anti-CD80 inhibits T cell activation and alleviates autoimmunity

  2022cites this paper
• Pathophysiology of Immune Checkpoint Inhibitor-Induced Myocarditis

  2022cites this paper
• The NOD Mouse Beyond Autoimmune Diabetes

  2022cites this paper
• Human adipose-derived mesenchymal stem cells prevent type 1 diabetes induced by immune checkpoint blockade

  2022cites this paper
• The Role of T Cell Receptor Signaling in the Development of Type 1 Diabetes

  2021cites this paper
• Dampening antiviral immunity can protect the host

  2021cites this paper
• Digestive Toxicities Secondary to Immune Checkpoint Inhibition Therapy - Reports of Rare Events. A Systematic Review.

  2021cites this paper
• Inducible Pluripotent Stem Cells as a Potential Cure for Diabetes

  2021cites this paper
• The immunoregulation of autoimmune diabetes

  2021cites this paper
• Microglial PD‐1 stimulation by astrocytic PD‐L1 suppresses neuroinflammation and Alzheimer’s disease pathology

  2021cites this paper
• Harnessing CD8+ T‐cell exhaustion to treat type 1 diabetes

  2021cites this paper
• The double-edged sword: Harnessing PD-1 blockade in tumor and autoimmunity

  2021cites this paper
• Mesenchymal Stem Cell‐Derived Extracellular Vesicles with High PD‐L1 Expression for Autoimmune Diseases Treatment

  2021cites this paper
• Immune Checkpoints and Innate Lymphoid Cells—New Avenues for Cancer Immunotherapy

  2021cites this paper